Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem‐cell transplantation is a prognostic marker of longer progression‐free survival and overall survival
- 5 April 2022
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 198 (2) , 278-287
Abstract
Immunoparesis is the suppression of normal polyclonal immunoglobulins and is present in most patients with newly diagnosed multiple myeloma (MM). The association of immunoparesis at diagnosis, and particularly its recovery along with treatment, with survival in patients ineligible for autologous stem-cell transplantation (ASCT) has not been well established. This retrospective study evaluated the impact of immunoparesis in 431 patients diagnosed with MM, ineligible for ASCT, with a median overall survival of 36 months [95% confidence interval (CI): 31-40]. Immunoparesis was present in 81.2% of patients at diagnosis and was associated with a trend to a worse overall response rate (ORR: 84.8% vs. 74.9%; OR 1.88 (95% CI: 0.97-3.63), shorter progression-free survival (PFS) [22.0 vs. 18.2 months; hazard ratio (HR) 0.775; 95%CI: 0.590-1.018; p = 0.066], and overall survival (OS) (45.9 vs. 34.2 months; HR 0.746; 95% CI: 0.551-1.010; p = 0.057). Twenty-four per cent of patients who had immunoparesis at diagnosis recovered polyclonal immunoglobulins in the follow-up period. Interestingly, these patients had a better ORR (96.3% vs. 68.2%; OR 12.29 (95% CI: 3.77-40.06), PFS (HR 0.703; 95CI%: 0.526-0.941; p = 0.018) and OS (HR 0.678; 95 CI%: 0.503-0.913; p = 0.011) than patients who did not recover it. In summary, restoring a healthy immune system along with first-line treatment in patients with MM, not receiving ASCT, is associated with better outcomes.Keywords
This publication has 39 references indexed in Scilit:
- Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myelomaLeukemia, 2014
- New Approaches to Smoldering MyelomaCurrent Hematologic Malignancy Reports, 2013
- Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUSLeukemia, 2012
- Smoldering (Asymptomatic) Multiple Myeloma: Current Diagnostic Criteria, New Predictors of Outcome, and Follow-Up RecommendationsJournal of Clinical Oncology, 2010
- Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myelomaLeukemia, 2009
- International uniform response criteria for multiple myelomaLeukemia, 2006
- Review of 1027 Patients With Newly Diagnosed Multiple MyelomaMayo Clinic Proceedings, 2003
- B‐lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B‐cell progenitors and plasma cell precursorsBritish Journal of Haematology, 1998
- Serum interleukin‐6 (IL‐6) and interleukin‐4 (IL‐4) in patients with multiple myeloma (MM)British Journal of Haematology, 1996
- Identification of early plasma cells in peripheral blood and their clinical significanceBritish Journal of Haematology, 1996